NCT07501858 Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metabolic Syndrome
| NCT ID | NCT07501858 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Center of New Medical Technologies |
| Condition | Metabolic Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2028-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2026-04-01 with a primary completion date of 2028-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This retrospective cohort study evaluates the association between H. pylori persistence and insulin resistance severity (HOMA-IR) in 100 patients with metabolic syndrome at Novosibirsk's Center for New Medical Technologies (CNMT). Patients are divided into infected (n=50) and non-infected (n=50) groups, assessing metabolic parameters, gastro panel, and CRP. Primary endpoint: HOMA-IR differences; secondary: correlations with gastric inflammation and metabolic markers.
Eligibility Criteria
Inclusion Criteria: * Verified MS per NCEP-ATP III criteria. * Ability to undergo all procedures (fasting blood draw, breath test, stool antigen, endoscopy/biopsy, anthropometry). Exclusion Criteria: * Current metabolic-influencing therapy. * Acute/chronic infection or autoimmune flare. * Interventional study participation in last 3 months. * Planned surgery/long hospitalization. * Active malignancies. * Severe liver/kidney failure. * Pregnancy/lactation. * Gastric resection or upper GI reconstruction. * Type 1 diabetes.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07501858 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Metabolic Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07501858 currently recruiting?
Yes, NCT07501858 is actively recruiting participants. Contact the research team at shrayner_ev@cnmt.ru for enrollment information.
Where is the NCT07501858 trial being conducted?
This trial is being conducted at Novosibirsk, Russia.
Who is sponsoring the NCT07501858 clinical trial?
NCT07501858 is sponsored by Center of New Medical Technologies. The trial plans to enroll 100 participants.